event presence logo
Innovative Strategies: Bispecific Antibodies for Relapsed/Refractory Follicular Lymphoma

CME/CNE/CPE

Hilton Chicago
Monday, June 3, 2024 | 6:45 pm - 7:45 pm CT
Supported by an independent educational grant from Genmab US, Inc. and AbbVie

overview

This live roundtable discussion will center on the advancing field of bispecific antibodies in relapsed/refractory follicular lymphoma (R/R FL). This program will include a dynamic rapid-fire Q&A format. Experts in the field of follicular lymphoma will discuss clinical trial data, adverse event management, the current treatment landscape, and key differences between approved and emerging bispecific antibodies.


Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.

faculty

MODERATOR

​​Gilles Salles, MD, PhD​

Professor of Medicine​

Chief of the Lymphoma Service​

Memorial Sloan Kettering Cancer Center​

Weill Cornell Medicine

New York, New York

PANELIST

Matthew Lunning, DO, FACP

Associate Professor

Medical Director

Cellular Therapy

Associate Vice-Chair Research

Department of Medicine

Assistant Vice Chancellor for Clinical Research

Fred & Pamela Buffett Cancer Center

University of Nebraska Medical Center

Omaha, Nebraska

PANELIST

Joshua Brody, MD

Director

Lymphoma Immunotherapy Program

Icahn School of Medicine at Mount Sinai

Hess Center for Science and Medicine

New York, New York

AGENDA

6:15 pm

Registration and Dinner

6:45 pm

Welcome and Introductions

Gilles Salles, MD, PhD

6:50 pm

The Future is Now: Bispecifics in Follicular Lymphoma

Gilles Salles, MD, PhD

7:10 pm

Adverse Event Management with Bispecific Antibodies in Follicular Lymphoma

Matthew Lunning, DO, FACP

7:25 pm

Bispecific Forecasting in Follicular Lymphoma: What You Need to Know

Joshua Brody, MD

7:40 pm

Closing Remarks and Q&A

All Faculty

LOCATION

Hilton Chicago

720 S Michigan Ave, Chicago, Illinois, 60605

Room: International South

GOAL STATEMENT

The goal of this activity is for learners to be better able to assess the most recent clinical data for bispecific antibodies for relapsed/refractory (R/R) FL and how these may be leveraged to differentiate between therapies and integrated into the management of R/R FL.

TARGET AUDIENCE

This activity is intended for hematologists, oncologists, oncology nurses, oncology nurse practitioners (NPs), physician assistants (PAs), oncology pharmacists, and other healthcare professionals (HCPs) who treat patients with follicular lymphoma (FL).

LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

  • Key differences between current and emerging bispecific antibodies used to treat R/R FL

Have greater competence related to

  • Managing adverse events (AEs) of bispecific antibody therapy

Demonstrate greater confidence in their ability to

  • Integrate the most recent data on bispecific antibodies into the management of R/R FL

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

accreditation logo
medscape logo

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

Awarded up to 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.

For Pharmacists

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-144-L01-P).

*/lbubrandlogo/*
© 2024 MedscapeLIVE! All Rights Reserved | Terms of Service | Privacy Policy